Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Pfizer (PFE) Tops Q4 EPS by 8c, Beats on Revenue; Offers FY26 Guidance
February 3, 2026 6:46 AM ESTPfizer (NYSE: PFE) reported Q4 EPS of $0.66, $0.08 better than the analyst estimate of $0.58. Revenue for the quarter came in at $17.58 billion versus the consensus estimate of $16.91 billion.
GUIDANCE:
Pfizer sees FY2026 EPS of $2.80-$3.00, versus the consensus of $2.97. Pfizer sees... More
